Maas BiolAB Announces That Cyclosporin Blocks Alzheimer's Model.Health/Medical Writers SAN DIEGO--(BW HealthWire)--Nov. 12, 2001 Maas BiolAB announced today that cyclosporin protected of the usually hardest hit cholinergic neurons in a rat model of Alzheimer's disease. Results from a new preclinical study were presented today at the 31st annual meeting of the Society for Neuroscience For other uses, see SFN (disambiguation). The Society for Neuroscience (SfN) is a professional society for basic scientists and physicians around the world whose research is focused on the study of the brain and nervous system. in San Diego by Cesar Borlongan Ph.D., neurodegeneration researcher at the National Institute of Health. Dr. Borlongan is Scientific Advisor to Maas BiolAB, and head of its Scientific Advisory Board. Maas is developing cyclosporin as a treatment for Alzheimer's and other neurodegenerative diseases. "CsA may promote better neuroprotection because of its multiple sites of action, such as preserving the integrity of calcium channels, blocking the mitochondria permeability transition pore, promoting neurotrophic factor support, and inhibiting free radicals," Borlongan explained. "Recent data have shown a direct correlation of increased tyrosine hydroxylase immunoreactivity in specific brain regions that display decreased calcineurin immunoreactivity. Similar correlations were noted between enhanced choline acetyltransferase immunoreactivity and decreased calcineurin," Dr. Borlongan reported. "Our observed cyclosporin enhancement of septal septal /sep·tal/ (sep´tal) pertaining to a septum. sep·tal adj. Of or relating to a septum or septa. ChAT immunoreactivity suggests potential therapeutic utility of cyclosporin for brain disorders characterized by alterations of the cholinergic system." "Maas will develop cyclosporin neuroprotection for Alzheimer's, Parkinson's, Huntington's and ALS Als (äls), Ger. Alsen, island, 121 sq mi (313 sq km), Sønderjylland co., S Denmark, in the Lille Bælt, separated from the mainland by the narrow Alensund. ," said Marcus Keep, M.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Maas. "Dr. Borlongan's innovative research and exciting results lead towards a cure for people suffering from Alzheimer's." "Unlike the briefly effective and transiently symptomatic dementia drugs like Aricept and Excelon, cyclosporin has the potential to stop the disease process itself by blocking massive neuronal apoptosis," said Eskil Elmer, Ph.D., Maas Scientific Director. "Dr. Borlongan has demonstrated that cyclosporin prevents the loss of the actual cells that make acetylcholine. No other drug does that." Maas BiolAB, LLC is developing therapeutics for CNS See Continuous net settlement. CNS See continuous net settlement (CNS). diseases based on cyclosporin neuroprotection. Cyclosporin is the most powerful known neuroprotectant in numerous animal models through its action as the only selective mitochondrial mitochondrial pertaining to mitochondria. mitochondrial RNAs a unique set of tRNAs, mRNAs, rRNAs, transcribed from mitochondrial DNA by a mitochondrial-specific RNA polymerase, that account for about 4% of the total cell RNA that pore blocker, and as neuroimmunophilin. Maas BiolAB has broad world patents for cyclosporin neuroprotection in numerous brain diseases including Alzheimer's, Parkinson's, ALS, Huntington's, HIV dementia, traumatic brain injury Traumatic brain injury (TBI), traumatic injuries to the brain, also called intracranial injury, or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from a closed head injury or a penetrating head injury and is one of two subsets of acquired brain , spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. and stroke. Visit www.maasbiolab.com for more insight. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion